Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer
Among patients with ovarian cancer treated since 2012, the overall RDI was low. Relative dose intensity was higher among patients with a BMI of 25 or higher compared with a BMI below 25. Most dose modifications occurred during treatment and not before initiation. Studies with body composition data and interventions that maximize chemotherapy completion during treatment are warranted.
Authors
- Denise Esserman (ORCID: https://orcid.org/0000-0003-1326-9618)
- Elena Ratner (ORCID: https://orcid.org/0000-0002-6277-6002)
- Leah M. Ferrucci (ORCID: https://orcid.org/0000-0001-9488-7586)
- Melinda L. Irwin (ORCID: https://orcid.org/0000-0001-7571-0304)
- Brenda Cartmel (ORCID: https://orcid.org/0000-0002-4748-5143)
- Tracy E. Crane
- Amanika Kumar
- Fang Yong Li
- Matthew P Schlumbrecht
- Anlan Cao
Institutions
- Mayo Clinic (US)
- University of Miami (US)
- Yale Cancer Center (US)
- Yale University (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
- Sylvester Comprehensive Cancer Center (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1093/jncics/pkaf121
- Primary Topic
- Cancer Risks and Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00